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Introduction
Ubiquitylation and proteolysis of cell cycle regulators is essen-
tial for control of the cell cycle. In particular, the anaphase-
promoting complex/cyclosome (APC/C) ubiquitin ligase regulates 
mitosis by directing the degradation of key substrates at differ-
ent times during mitosis. The APC/C is regulated at several lev-
els to ensure that (1) its activity is restricted to mitosis and G1 
phase and that (2) it recognizes specifi  c substrates at specifi  c 
times. This is achieved through its phosphorylation in mitosis, 
through its interaction with coactivators (including Cdc20 and 
Cdh1), and by inhibitors such as regulator of cyclin A 1 (Rca1)/
early mitotic inhibitor 1 (Emi1; Harper et al., 2002; Peters, 
2002; Castro et al., 2005).
Interaction between the APC/C and its two coactivators is 
regulated during the cell cycle (for review see Peters, 2006). 
Cdc20 can only interact with the phosphorylated form of APC/C 
that is specifi  c to mitosis and is itself degraded after meta-
phase, thereby restricting its activity to the fi  rst part of mitosis. 
In contrast, Cdh1 can interact with both the interphase and mi-
totic forms of the APC/C, and its binding depends on its phos-
phorylation status. In budding yeast, Cdh1 is phosphorylated by 
B-type cyclin–Cdk complexes from S phase to anaphase, and 
this prevents it from binding to the APC/C. The Cdc14 phos-
phatase subsequently dephosphorylates Cdh1 at mitotic exit 
(Zachariae et al., 1998; Jaspersen et al., 1999), and the Cdh1-bound 
form of the APC/C (APC/C
Cdh1) aids mitotic exit and regulates 
G1 phase. Cdh1 is phosphorylated in metazoans too, and this 
also prevents its binding to APC/C (Lukas et al., 1999; Kramer 
et al., 2000; Sorensen et al., 2001). However, how Cdh1 phos-
phorylation is regulated during the cell cycle is less clear.
In metazoans, APC/C
Cdh1 is negatively regulated in inter-
phase in Drosophila melanogaster by Rca1 and in mammalian 
and Xenopus laevis cells by the orthologous protein Emi1. The 
Drosophila protein Rca1 was originally identifi  ed as a regulator 
of cyclin A whose mutation induces an arrest in G2 phase of cell 
cycle 16, which is similar to that observed in cyclin A mutants 
(Dong et al., 1997). Rca1 mutant cells block in G2 phase and 
prematurely degrade mitotic cyclins in a Cdh1-dependent man-
ner (Grosskortenhaus and Sprenger, 2002). Similarly, in Xenopus 
extracts, Emi1 immunodepletion prevents mitotic entry, and 
cyclins are prematurely degraded (Reimann et al., 2001a).
Emi1 was originally identifi  ed in a yeast two-hybrid screen 
for F-box proteins using Skp1 as bait (Reimann et al., 2001a). 
Emi1 also contains a zinc-binding domain that is important for 
APC/C inhibition. Emi1 levels are regulated during the cell 
cycle: in mammalian cells, its transcription is induced at the G1/S 
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transition under the control of E2F, and this has been reported to 
be required to stabilize cyclin A and allow cells to begin S phase 
(Hsu et al., 2002). Overexpressing Rca1 in G1-phase cells has 
also recently been shown to promote S phase in Drosophila em-
bryos in an F-box–dependent manner (Zielke et al., 2006). Emi1 
is subsequently degraded at the entry to mitosis (Reimann et al., 
2001a; Castro et al., 2005) by the SCF
β-TrCP ubiquitin ligase 
(Guardavaccaro et al., 2003; Margottin-Goguet et al., 2003). 
SCF
β-TrCP recognizes Emi1 only after it has been phosphory-
lated by Plk1 (Hansen et al., 2004; Moshe et al., 2004), which 
creates the phosphodegron DSGxxS. Recently, the Evi5 protein 
has been reported to stabilize Emi1 in S and G2 phases by 
blocking its phosphorylation by Plk1 (Eldridge et al., 2006).
Emi1 has been proposed to have a wider role than Rca1 by 
acting on APC/C
Cdc20 as well as APC/C
Cdh1 and, thus, to play a 
key role in controlling activation of the APC/C in mitosis. Emi1 
has been reported to inhibit APC/C
Cdc20 when cells begin mito-
sis such that its degradation is essential for APC/C
Cdc20 activa-
tion and the degradation of mitotic regulators (such as cyclins A 
and B and securin; Reimann et al., 2001a; Margottin-Goguet 
et al., 2003). Excess Emi1 inhibits cyclin B ubiquitylation when 
added to an in vitro ubiquitylation assay, and excess Emi1 added 
to Xenopus egg extracts prevents cyclins A and B, securin, and 
geminin degradation (Reimann et al., 2001a). Furthermore, 
overexpressing Emi1 in vertebrate cells induces a delay in mito-
sis (Reimann et al., 2001a; Hsu et al., 2002), which has been 
  interpreted as evidence that it inhibits Cdc20. In contrast, 
  genetic interactions in Drosophila are not consistent with a role 
for Rca1 in the inhibition of Cdc20 (Grosskortenhaus and 
Sprenger, 2002).
In this study, we have investigated the role and regulation 
of Emi1 in mammalian cells in vivo. We fi  nd that Emi1 is nor-
mally degraded in prophase but that a nondegradable version of 
Emi1 has no effect on the timing or extent of cyclin A destruc-
tion nor on the destruction of the majority of cyclin B1 and se-
curin. Thus, we show that Emi1 does not regulate activation of 
the APC/C at mitosis. Rather, we fi  nd that the major require-
ment for Emi1 is to allow the accumulation of mitotic cyclins 
and geminin in G2 phase in order to allow cells to enter mitosis 
and to prevent rereplication.
Results
Emi1 is degraded in prophase before 
the APC/C is activated
We set out to test the role of Emi1 in regulating the APC/C at 
mitosis. We used a commercial antibody to characterize Emi1 
in human cells. We confi  rmed that the antibody is specifi  c for 
Emi1 because it recognized a band of the correct size ( 50 kD) 
on an immunoblot of whole cell lysate (Fig. 1 and Fig. S1 A, 
lane 1; available at http://www.jcb.org/cgi/content/full/jcb
.200611166/DC1) that decreased after treating cells with 
siRNA oligonucleotides specifi  c for Emi1 (Fig. S1 A, lanes 4–5). 
Furthermore, it recognized higher molecular mass bands of the 
correct size after transfecting plasmids encoding HA-tagged or 
fl  uorescent protein-tagged forms of Emi1 into human tissue 
culture cells (Fig. S1 A, lanes 2–3). A minor faster migrating 
band was also reproducibly detected whose signifi  cance is un-
known but seemed to be related to Emi1, as it also disappeared 
after siRNA treatment (Fig. S1 A). Using this antibody, Emi1 
protein levels were analyzed in HeLa cells synchronized by a 
thymidine/aphidicolin block and release regime (see Materials 
and methods); samples were collected during S and G2 phases 
and mitosis. The cell cycle phase was monitored by fl  ow cyto-
metry, which showed that most of the cells passed through mitosis 
between 12 and 15 h after release from the aphidicolin block. 
Emi1 levels decreased 11 h after release (Fig. 1 A), when most 
of the cells were in late G2 phase or mitosis, and before cyclin 
B1 levels decreased at 13 h, which is consistent with a previous 
study (Hsu et al., 2002). This was  2 h after we could detect 
an increase in Plk1 activity as judged by phosphorylation on 
S133 of cyclin B1, a known Plk1 phosphorylation site (Fig. 1 A; 
Jackman et al., 2003).
The degradation of Emi1 had been reported to be essential 
for activation of the APC/C at mitotic entry and, thus, for the 
degradation of early mitotic regulators, including cyclin A. 
Therefore, it was important to characterize the exact timing of 
Emi1 degradation. With this aim, we generated a chimeric pro-
tein in which the Venus fl  uorescent protein (Nagai et al., 2002) 
was fused to the N terminus of Emi1. A plasmid encoding 
 Venus-Emi1 was injected into HeLa cells in G2 phase, and the fl  uo-
rescence levels were measured as a read-out for Emi1 degradation. 
Venus-Emi1 started to be degraded in prophase usually before or 
occasionally at nuclear envelope breakdown (NEBD; Fig. 1 C), 
as determined by differential interference contrast (DIC) images 
(Fig. 1 B). The earliest time we observed Emi1 proteolysis to 
start was 20 min before NEBD. We also analyzed Emi1 degrada-
tion in the nontransformed hTert–retinal pigment epithelium 
(RPE) cell line and observed very similar timings (Fig. S1 B). 
In vitro, Emi1 has to be phosphorylated by Plk1 before it can be 
degraded (Hansen et al., 2004; Moshe et al., 2004), and the tim-
ing that we observe for Emi1 degradation is consistent with the 
time when Plk1 is activated (Golsteyn et al., 1995).
A β-TrCP recognition site (DSGxxS) had been identifi  ed 
in Emi1 (Guardavaccaro et al., 2003; Margottin-Goguet et al., 
2003), and mutating either Asp or Gly in this motif prevented 
the recognition of other substrates by β-TrCP (Liu et al., 2002). 
Therefore, we generated two different Emi1 mutants (D144A 
and G146V) in the β-TrCP recognition site and tested their sta-
bility. Both mutants were stable in HeLa (Fig. 1 D) and hTert-
RPE (Fig. S1 C) cells progressing through G2 phase and 
mitosis, confi  rming that the β-TrCP site was required for the 
degradation of Emi1 in prophase. We also generated a mutant 
(S145A/S149A) to ablate phosphorylation by Plk1 and found 
that this also stabilized Emi1 in mitosis (Fig. 1 D), which is 
consistent with previous studies (Guardavaccaro et al., 2003; 
Margottin-Goguet et al., 2003; Hansen et al., 2004). In most of 
the experiments described in this and the next section, each of 
the D144A and G126V degradation mutants and the S145A/
S149A phosphorylation mutants were used to rule out any 
 effects  specifi  c to only one mutant. We could also demonstrate 
that the S145A/S149A mutant retained its biological activity by 
using it to rescue cells depleted of endogenous Emi1 by siRNA 
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The timing of Venus-Emi1 degradation with respect to 
NEBD was variable and, in some cases, started 20 min before 
NEBD; in comparison, the earliest mitotic APC/C substrates   
(e.g., cyclin A) are degraded at or after NEBD (den Elzen and 
Pines, 2001; Geley et al., 2001). When we compared the timing 
of Emi1 and cyclin A degradation in the same cell using Venus-
Emi1 and cyclin A–CFP, we found that these were also variable 
and that Emi1 began to be degraded anywhere between 6 and 
45 min (mean of 26 min; n = 8), before cyclin A. This made it 
unlikely that Emi degradation was the trigger that directly acti-
vated APC/C
Cdc20 at mitosis, although it could still be a prereq-
uisite to activate APC/C
Cdc20.
Emi1 degradation is not required 
to activate the APC/C
To determine whether Emi1 had to be degraded to activate APC/
C
Cdc20, we injected wild-type and nondegradable Emi1 con-
structs into cells and assayed the effect on the degradation of the 
three most well-characterized substrates of APC/C
Cdc20: cyclin A, 
cyclin B1, and securin. We assayed both the timing of degra-
dation in vivo and the level of endogenous proteins remaining in 
cells arrested in mitosis after the injection of Emi1.
When we injected RNA encoding nondegradable Emi1 at 
1 μg/μl, this produced levels of Emi1 similar to those found in 
previously published transient transfection experiments, and we 
found that as reported, cells delayed in mitosis (Reimann et al., 
2001a; Hsu et al., 2002; Margottin-Goguet et al., 2003). How-
ever, in these experiments, Emi1 was expressed at 10–30-fold 
more than its endogenous level (see Materials and methods; 
Lehman et al., 2006). Thus, the delay in mitosis might not be 
apparent if we expressed Emi1 closer to its normal levels, which 
would be consistent with cells lacking β-TrCP (and thus unable 
to degrade Emi1) that only exhibit a slight delay ( 30 min) 
in exit from mitosis after release from a nocodazole block 
(Guardavaccaro et al., 2003). Therefore, we reduced the amount 
of RNA encoding nondegradable Emi1 between 2- and 10-fold 
(0.1 and 0.5 μg/μl) and found that 51% of cells (n = 45) ex-
pressing lower amounts of Emi1 were able to perform anaphase 
successfully and reenter interphase. This indicated that the cells 
must have activated the APC/C and degraded most or all of their 
securin and mitotic cyclins.
The delay in mitosis seen with high levels of nondegrad-
able Emi1 had been attributed to inhibition of the APC/C and, in 
particular, protecting cyclin A from destruction. To determine 
whether the timing of cyclin A degradation was affected by high 
levels of nondegradable Emi1, we analyzed cyclin A degrada-
tion in living cells after coinjection with high levels of any of the 
three nondegradable Emi1 mutants. We found that cyclin A–CFP 
degradation was unaffected by the presence of Emi1 (Fig. 2 A). 
To rule out any possible artifact caused by the presence of the 
Figure 1.  Emi1 is degraded in prophase. (A) Emi1 levels 
were analyzed by Western blotting in extracts from HeLa cells 
synchronized at the G1/S transition by thymidine/aphidico-
lin block and then released and followed through S and G2 
phases and mitosis. Cyclin B1 levels were also analyzed. 
Anti–cyclin B1 S133 phosphospeciﬁ  c antibody was used as a 
read-out of Plk1 activity. Hsp70 and actin were used as load-
ing controls. Molecular mass markers (given in kilodaltons) 
are shown. (B) HeLa cells injected with Emi1 were followed 
by video microscopy through G2 phase and mitosis. The DIC 
images were used to determine the different phases and mi-
totic stages. Time (given in minutes) is shown taking NEBD as 
t = 0. In general, cells expressing ectopic Emi1 took slightly 
longer to complete mitosis than control cells. (C) Quantiﬁ  ca-
tion of ﬂ  uorescence levels of the cell shown in B. Time of NEBD 
and anaphase are indicated. Representative of 39 cells from 
11 experiments. (D) Two different mutants in the β-TrCP recog-
nition site (D144A and G146V) and the S145A/S149A 
phosphorylation site mutant are stable after injection in HeLa 
cells. Representative of 43 cells from 10 experiments for 
D144A mutant, 44 cells from eight experiments for G146V 
mutant, and 30 cells from ﬁ  ve experiments for the S145A/
S149A mutant. JCB • VOLUME 177 • NUMBER 3 • 2007  428
tag on Emi1, we also analyzed cyclin A degradation in cells 
coinjected with untagged Emi1 D144A expressed from an inter-
nal ribosome entry site (IRES) vector coexpressing GFP and 
obtained similar results (Fig. S2 A, available at http://www.jcb
.org/cgi/content/full/jcb.200611166/DC1). Similarly, the timing 
of cyclin B1 and securin degradation, which starts at metaphase 
(Clute and Pines, 1999; Hagting et al., 2002), was unaffected 
when nondegradable Emi1 mutants were coinjected with cyclin 
B1–CFP (Fig. 2 B) or securin-Cerulean (Fig. 2 C). Similar re-
sults were obtained when the wild-type version of Venus-Emi 
was coinjected with cyclins A and B1 or securin (unpublished 
data). Thus, APC/C
Cdc20 is activated upon entry to mitosis re-
gardless of the presence of even supraphysiological levels of 
Emi1. Although the timing of securin destruction was un-
affected, we did fi  nd that its extent was more sensitive to the 
levels of Emi1 than either cyclin A or B1 destruction.
We also analyzed the levels of the endogenous cyclins 
and securin in cells arrested in mitosis by high levels of non-
degradable Emi1. Each of the three nondegradable Emi1 mutants 
were injected separately into G2-phase HeLa cells, and cells were 
followed by time-lapse DIC microscopy. After the cells were 
delayed for >2 h in mitosis, they were fi  xed and processed for 
immunofl  uorescence. Although immunofl  uorescence is not a 
truly quantitative approach, the relative levels of cyclins A and 
B1 and securin in noninjected control cells at different stages of 
mitosis were consistent with the known timings of their degra-
dation. In noninjected cells, cyclin A levels were maximal in G2 
phase and prophase, decreased in prometaphase and metaphase, 
and were almost undetectable in anaphase and telophase cells 
(Fig. 2 D), which is consistent with cyclin A degradation start-
ing in prometaphase (den Elzen and Pines, 2001; Geley et al., 
2001). The immunofl  uorescence signal of endogenous cyclin A 
in cells expressing high levels of a nondegradable Emi1 that had 
delayed in a metaphase-like state was similar to the intensity 
of noninjected anaphase/telophase cells (Fig. 2 D), indicating 
that, like the cyclin A–CFP marker, endogenous cyclin A was 
degraded completely as normal. The three nondegradable Emi1 
mutants produced identical results.
Cyclin B1 degradation normally starts when the spindle 
checkpoint is satisfi  ed at metaphase (Clute and Pines, 1999). 
Consistent with this, we observed maximum cyclin B1 levels in 
prometaphase control noninjected cells, whereas the signal was 
Figure 2.  The timing of degradation of cyclins 
A and B1 and securin is not affected by the 
presence of Emi1. (A) Cyclin A–CFP: HeLa cells 
were coinjected in G2 phase with Venus-Emi1 
D144A and cyclin A–CFP and followed by 
time-lapse microscopy. The ﬂ  uorescence levels 
of both proteins were measured and plotted 
over time. NEBD was determined from the DIC 
images. This result is representative of four cells 
from two experiments with Venus-Emi1 D144A, 
14 cells from three experiments with Venus-
Emi1 G146V, and eight cells from ﬁ  ve experi-
ments with Venus-Emi1 S145A/S149A. The 
apparent decrease of Venus-Emi1 D144A ﬂ  uo-
rescence is the result of photobleaching. (B) Cy-
clin B1–CFP: HeLa cells were coinjected in G2 
phase with Venus-Emi1 D144A and cyclin B1–
CFP and analyzed as in A. This result is repre-
sentative of 15 cells in six experiments with 
Venus-Emi1 D144A and six cells in three exper-
iments with Venus-Emi1 G146V. (C) Securin-
Cerulean: HeLa cells were coinjected in G2 phase 
with Venus-Emi1 D144A and securin-Cerulean 
followed by time-lapse ﬂ  uorescence  micros-
copy, and the ﬂ   uorescence levels were mea-
sured and analyzed as in A and B. This result is 
representative of seven cells in three experi-
ments with Venus-Emi1 D144A. Note that in 
these experiments, lower amounts of Venus-
Emi1 D144A were injected. (D) Cyclin A: HeLa 
cells injected with Venus-Emi1 D144A in G2 
phase were followed by time-lapse microscopy 
and ﬁ  xed after they had delayed in metaphase. 
Cells were stained for cyclin A, and the levels 
were quantiﬁ   ed in the injected arrested cells 
and in control noninjected cells at different 
stages. The quantiﬁ  cation shown is of PFA-ﬁ  xed 
cells, and similar results were obtained after 
methanol/acetone ﬁ  xation. Similar results were 
obtained with two different cyclin A antibodies. 
Results are representative of four experiments. 
(E) Cyclin B1 levels analyzed on cells injected, 
ﬁ  lmed, and stained as in D. The quantiﬁ  cation shown is of cells ﬁ  xed in methanol/acetone, and similar results were obtained after PFA ﬁ  xation. Results are 
representative of ﬁ  ve experiments. (F) HeLa cells that delay in mitosis after Venus-Emi1 D144A injection (blue in the merge) were ﬁ  xed and stained with CREST 
serum (red in the merge) and aurora B antibodies (green in the merge). Representative of 11 cells analyzed. Bar, 15 μm.EMI1 COUPLES DNA REPLICATION AND MITOSIS • DI FIORE AND PINES 429
almost undetectable in anaphase and telophase cells (Fig. 2 E). 
When we analyzed the cells delayed by high levels of Emi1, we 
found that cyclin B1 levels were lower than in control prometa-
phase or metaphase cells but not as low as in control anaphase 
and telophase cells (Fig. 2 E). This showed that the bulk of 
  cyclin B1 had been degraded but that a fraction of cyclin B1 
  remained, accounting for the cells delaying in mitosis. To rule 
out any artifact caused by the presence of the tag, we quantifi  ed 
the levels of either endogenous cyclins A (Fig. S2 B) or B1 (Fig. 
S2 C) in cells that had delayed in mitosis after injecting un-
tagged Emi1 D144A expressed from an IRES vector. For both 
cyclins, results were identical to those obtained with Venus-
D144A injection (Fig. 2, D and E).
Staining Emi1-arrested cells for endogenous securin showed 
that some securin also remained (unpublished data), which was 
consistent with the cells delaying in metaphase, and we confi  rmed 
that the sister chromatids were still attached by staining the cells 
with anti–Aurora B and autoimmune CREST antibodies to visu-
alize the kinetochores and centromeres (Fig. 2 F).
To assay the effect of Emi1 on mitosis in nontransformed 
cells, we used hTert-RPE cells. Cells were stimulated to reenter 
in the cell cycle after serum starvation and were injected with 
nondegradable Emi1 when they had reached G2 phase. With 
high levels of Emi1, these cells also delayed in mitosis. We 
fi  xed the cells, measured the levels of endogenous cyclins A and 
B1 by immunofl  uorescence, and compared these with the levels 
in control noninjected cells. We found that as in HeLa cells, en-
dogenous cyclins A and B1 had been degraded (Fig. S2, D and E). 
Thus, in both normal and transformed cells, Emi1 did not have 
to be degraded for all of cyclin A and the bulk of cyclin B1 to 
be destroyed. Although a fraction of cyclin B1 remained in 
cells expressing supraphysiological levels of Emi1, cyclin B1 
destruction began at its normal time. In all, these results are 
clearly inconsistent with the model that Emi1 degradation acti-
vates APC/C
Cdc20 and with the proposal that Emi1 is required to 
stabilize cyclin A in early mitosis.
Emi1 regulates mitotic entry, stabilizing 
cyclins A and B1
Because Emi1 did not appear to control activation of the mitotic 
APC/C, we investigated its role in the cell cycle by depleting 
it by siRNA. Two different siRNA duplexes specifi  c for Emi1 
(siEmi1_1 and siEmi1_2) were effective in reducing Emi1 pro-
tein levels, although to different extents (see Fig. 5 A). To ana-
lyze the effects of reducing Emi1 levels during the cell cycle, 
synchronized cells were treated with siRNA, and cells were an-
alyzed by fl  ow cytometry. Emi1 siRNA–treated cells arrested 
at the G1/S transition in an aphidicolin block and progressed 
through S and G2 phase after release from aphidicolin in a simi-
lar manner to that of control siRNA–treated cells (Fig. 3 A). 
  Labeling cells with short pulses of BrdU to reveal the pattern of 
replication foci in S phase showed that Emi1-depleted cells also 
resembled control cells in having many evenly distributed foci 
in early S phase and fewer foci that tend to be closer to the nu-
clear envelope in mid- to late S phase (Fig. 3 B; Nakayasu and 
Berezney, 1989). These changes likely refl  ect the fi  ring of early, 
mid-, and late origins of replication. However, Emi1-depleted 
cells differed from controls in that the foci persisted after cells 
had reached a 4N DNA content as judged by fl  ow cytometry.
Around 15 h after release from the aphidicolin block, 
most of the control cells had progressed through mitosis, and 
the bulk of the cells had entered the following G1 phase (2N 
DNA content) after 20 h (Fig. 3 A). However, at these time 
Figure 3.  Emi1 is required for mitotic entry. (A) Thymidine/aphidicolin-
synchronized cells were transfected during the release from thymidine with 
either control (left) or Emi1_1 (right) siRNA oligonucleotides. Cells were 
analyzed at various times after aphidicolin release by propidium iodide 
staining and ﬂ  ow cytometry. The time indicates hours after aphidicolin re-
lease. Representative of two experiments. (B) Cells were transfected as in A, 
labeled with BrdU for 30 min before ﬁ  xation, and stained with anti-BrdU 
antibodies at the indicated times after release from an aphidicolin block. 
Total DNA was stained with Hoechst 33342. Bar, 10 μm. JCB • VOLUME 177 • NUMBER 3 • 2007  430
points, cells treated with siRNA targeting Emi1 accumulated 
with a 4N DNA content. At 40 h after release from the G1/S 
block, only a minor fraction of these cells had entered the next 
cell cycle (Fig. 3 A); most of the cells had increased in ploidy 
compared with control cells (Fig. 3 A and see Fig. 5).
To determine whether depleting Emi1 caused a block in 
G2 phase or mitosis, siRNA-treated cells were followed by 
time-lapse microscopy 11 h after release from an aphidicolin 
block. Fig. 4 A shows the cumulative total of cells that entered 
mitosis as judged by NEBD. Only a minor fraction of cells 
transfected with siRNA against Emi1 entered mitosis (Fig. 4 A), 
indicating that the cells accumulating in the 4N DNA peak ob-
served by fl  ow cytometry were delayed in G2 phase and not in 
mitosis. Similar results were obtained with an independent 
siRNA oligonucleotide specifi  c for Emi1 (Fig. S3, available at 
http://www.jcb.org/cgi/content/full/jcb.200611166/DC1).
In Drosophila cells and Xenopus egg extracts, mitotic en-
try was blocked when Rca1 or Emi was mutated or depleted 
(Reimann et al., 2001a; Grosskortenhaus and Sprenger, 2002), 
and this correlated with a failure to accumulate mitotic cyclins. 
To test whether this was also the case in mammalian cells, we 
collected samples at the same time points as for fl  ow cytometry 
analysis and analyzed the levels of Emi1 and cyclins A and B1 
by immunoblotting. In cells treated with the control siRNA oli-
gonucleotides, Emi1 levels decreased 12–15 h after release 
from a G1/S block, when most of the cells were entering mito-
sis. As expected, cyclin A levels decreased with a similar tim-
ing, whereas cyclin B1 levels decreased later (Fig. 4 B). In stark 
contrast, in Emi1-depleted cells, cyclin A and B1 levels were 
almost undetectable (Fig. 4 B). Treating Emi1-depleted cells 
with a proteasome inhibitor caused cyclin A to accumulate, 
showing that Emi1 was indeed required to stabilize it (Fig. 4 C). 
Thus, the impairment in mitotic entry in Emi1-depleted cells 
correlated with a failure to accumulate cyclins A and B1.
Emi1 is required to prevent rereplication
In budding and fi  ssion yeasts and in Drosophila cells, the mi-
totic cyclins have an important role in preventing rereplication, 
which might provide an explanation for the increase in ploidy 
in Emi1-depleted cells after 40 h (Fig. 3 A). However, in human 
cells, geminin has been implicated as the primary block to re-
replication (Melixetian et al., 2004; Zhu et al., 2004). To study 
this further, we depleted Emi1 by siRNA in asynchronous HeLa 
and hTert-RPE cells and harvested the cells 24, 48, and 72 h after 
transfection. We used two different siRNA oligonucleotides to 
deplete Emi1, one of which (Emi1_2) was less effective than the 
other (Emi1_1), particularly at later time points (Fig. 5 A). Flow 
cytometry analysis showed that in contrast to cells treated with 
the control oligonucleotides, which continued to proliferate nor-
mally, most of the cells treated with the Emi1 siRNA oligonucle-
otides accumulated with a 4N DNA peak 24 h after transfection 
(Fig. 5 B), as we had observed in synchronized cells (Fig. 3 A). 
At later time points (48 and 72 h after transfection), a substantial 
number of cells became polyploid (Fig. 5 B), and this correlated 
with the appearance of enlarged nuclei (Fig. 5 C). Nuclei became 
even larger 72 h after transfection, indicating that the cells were 
actively replicating their DNA. We confi  rmed that the increase 
in polyploidy and enlarged nuclear size were caused by extra 
rounds of DNA replication by labeling cells with BrdU and mea-
suring DNA synthesis by fl  ow cytometry (Fig. S4 A, available at 
http://www.jcb.org/cgi/content/full/jcb.200611166/DC1).
The rereplication phenotype was more pronounced with 
oligonucleotide siEmi1_1 than with siEmi1_2, which is consis-
tent with the more effi  cient knockdown observed by immuno-
blotting (Fig. 5 A). Cells treated with the siEmi1_2 siRNA 
oligonucleotides showed a partial phenotype both by fl  ow cy-
tometry and the number of enlarged nuclei visible after Hoechst 
staining. In particular, the rereplication phenotype seemed to be 
reduced 72 h after transfection, most likely because the prolifer-
ating nontransfected cells diluted out the rereplicating cells that 
were still visible as large nuclei (Fig. 5 C).
We confi  rmed these results in nontransformed hTert-RPE 
cells. Here, the phenotype was slightly less pronounced, which 
is consistent with a less effi  cient reduction in Emi1 levels (Fig. 
S4 B). Nevertheless, reducing Emi1 levels caused hTert-RPE 
cells to become polyploid (Fig. S4 C) with greatly enlarged 
Figure 4.  Emi1 is required to accumulate cyclins A and B1. (A) Cumulative 
number of cells entering mitosis (NEBD) plotted over time, as observed by 
time-lapse DIC microscopy of cells transfected with either control or Emi1_1 
siRNA. Representative of three experiments. (B) Emi1 and cyclins A and B1 
levels in cells transfected with either control or siEmi1_1 siRNA were ana-
lyzed by Western blotting. These samples correspond to the time points 
  after release from a G1/S block as shown in Fig. 3 A. Actin and Hsp70 
are shown as loading controls. The asterisk marks residual Emi1 signal. 
The same extracts were run on two different gels (top and bottom), and a 
loading control is shown for each gel. Results are representative of two 
  experiments. (C) HeLa cells were transfected with either control (siCTR) or 
Emi1 (siEmi1_1) siRNA oligonucleotides, and, 24 h after transfection, 
MG132 was added for 6 h. Actin is shown as a loading control. The asterisk 
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  nuclei (Fig. S4 D). Together, these results indicated that Emi1-
depleted cells undergo extra rounds of DNA replication.
To prove the specifi  city of this phenotype, we cotransfected 
siRNA oligonucleotides with an expression plasmid encoding Emi1. 
The siEmi1_1 siRNA oligonucleotide is directed against the STOP 
codon of Emi1 and its 3′ untranslated region; the Venus-Emi1 con-
struct does not contain the 3′ untranslated region and is thus 
  resistant to siRNA. Control and Emi1 siRNA duplexes were 
  cotransfected with either a plasmid expressing Venus-Emi1 or an 
empty vector expressing Venus. Because the size of the nuclei 
correlates with the degree of ploidy (Fig. 5 C), we measured the 
area of the fl  uorescent nuclei when the Emi1 or control oligo-
nucleotides were cotransfected with either pVenus or pVenus-
Emi1. The nuclei of cells cotransfected with pVenus and the 
Emi1 siRNA oligonucleotides had clearly increased in size 
(Figs. 5 D and S4 E), which is similar to those in which the 
siRNA oligonucleotides alone were transfected (Fig. 5 C). 
In contrast, cotransfecting pVenus-Emi1 with the Emi1 siRNA 
oligonucleotides prevented the increase in nuclear size (Figs. 5 D 
and S4 E). Cotransfecting pVenus-Emi1 did not have a major 
effect on the size of nuclei in cells transfected with control siRNA 
oligo nucleotides (Figs. 5 D and S4 E).
To rule out the possibility that cells cotransfected with 
pVenus-Emi1 and the Emi1 siRNA oligonucleotides did not re-
replicate their DNA because the cells arrested in the cell cycle, 
we labeled cells with BrdU to measure DNA synthesis. In cells 
cotransfected with siRNA oligonucleotides against Emi1 and 
either the empty vector or Emi1-expressing plasmid, most of 
the cells were positive for BrdU, indicating that they were pro-
liferating (unpublished data).
Rereplicating cells show increased levels 
of cyclin E and low levels of cyclins A and B1 
and geminin
Previous studies had shown that both cyclins A and E are capa-
ble of stimulating DNA replication; therefore, we predicted that 
Figure 5.  Emi1 is required to prevent rereplication. (A) Asynchronous HeLa cells were transfected with control or two different Emi1 siRNAs, and Emi1 levels 
were analyzed by Western blotting 24, 48, and 72 h after transfection. Actin is shown as a loading control. Results are representative of four experiments. 
(B) DNA content of cells transfected as in A and analyzed by ﬂ  ow cytometry after staining with propidium iodide. Results are representative of four experi-
ments. (C) Cells transfected as in A were stained with Hoechst to visualize the nuclei. Bars, 30 μm. (D) Cells cotransfected with control and Emi1 siRNAs plus 
expression vectors encoding Venus (control) or Venus-Emi1 (as indicated) were ﬁ  xed 48 and 72 h after transfection, and DNA was stained with Hoechst. The 
nuclear size (in pixels on the y axis) was measured using ImageJ software. The small bars in the dot plot show the minimum and maximum values, and the 
box shows the ﬁ  rst and third quartiles. The bar in the box is the median value. Outliers (closed circles) and suspected outliers (open circles) as determined by 
statistical analysis are shown. Results are representative of two independent experiments. More than 100 nuclei were measured for each sample.JCB • VOLUME 177 • NUMBER 3 • 2007  432
cells lacking cyclin A through the depletion of Emi1 might be 
able to rereplicate their DNA because they contained cyclin E. 
Therefore, we assayed siRNA-treated cells for the levels of cy-
clins A, B1, and E. We found that cells depleted of Emi1 had 
very low levels of cyclins A and B1 but higher than normal lev-
els of cyclin E (Fig. 6 A), which is consistent with the idea that 
cyclin E–Cdk activity was driving the rounds of rereplication. 
To assay whether cyclin E–Cdk2 was responsible for driving 
DNA synthesis, we treated Emi1-depleted cells with roscovitine 
to inhibit Cdk2 and found that this blocked rereplication (Fig. 6 B), 
and the cells remained with a 4N DNA content.
As mentioned in the previous paragraph, another APC/C 
substrate, geminin, is required to prevent rereplication in several 
human cell lines. Geminin binds, inactivates, and apparently 
stabilizes Cdt1, which loads the minichromosome maintenance 
(MCM) protein complex onto DNA origins. We assayed the 
  levels of geminin and Cdt1 on immunoblots and found that 
geminin and Cdt1 were substantially reduced in Emi1-depleted 
cells compared with control cells, whereas Cdc6 did not appear 
to change substantially (Fig. 6 C). Thus, Emi1 is required to sta-
bilize the mitotic cyclins, geminin, and Cdt1 in interphase cells.
Emi1 is required to antagonize Cdh1
In Drosophila, Rca1 has been shown to be epistatic to fi  zzy re-
lated, the homologue of Cdh1. To determine whether APC/C
Cdh1 
was responsible for degrading cyclins A and B1 in cells depleted 
of Emi1, we cotransfected cells with siRNA duplexes targeting 
Emi1 and Cdh1 and assayed the effect on cell division and cy-
clin levels. Cells were transfected with siRNA duplexes against 
Emi1 together with either control oligonucleotides or in combi-
nation with siRNA oligonucleotides targeting Cdh1 or an equal 
amount of control duplex, and protein levels were assayed by 
immunoblotting (Fig. 7 A). This revealed that codepleting Cdh1 
antagonized the effect of depleting Emi1 such that cyclin A 
could then accumulate (Fig. 7 A), as did cyclin B1 and geminin 
(Fig. 7 A). In agreement with this, in cells depleted of both 
Emi1 and Cdh1, nuclear size was very similar to control trans-
fected cells and much smaller than Emi1-depleted cells (Fig. 
7 B), indicating that codepleting Cdh1 stopped rereplication in 
cells lacking Emi1. Furthermore, the cell number of Emi1-
  depleted cells was much lower than control cells, as one would 
expect from rereplicating cells that stop dividing, whereas there 
were a similar number of control and Emi1/Cdh1-codepleted 
cells at 72 h after transfection, indicating that these cells were 
proliferating. In contrast, codepleting Cdc20 had no effect on 
the rereplication phenotype (unpublished data), which was to be 
expected because we found that Cdc20 was unstable in Emi1-
depleted cells (unpublished data).
Flow cytometry analysis confi  rmed these conclusions: in 
contrast to cells depleted of Emi1 that arrested with a 4N DNA 
content, which increased overtime as the DNA was rereplicated, 
cells depleted of both Emi1 and Cdh1 entered and then exited 
mitosis (Fig. S5, available at http://www.jcb.org/cgi/content/
full/jcb.200611166/DC1) with a similar time course to control 
cells. Assaying cell division by trapping mitotic cells with taxol 
and measuring the cumulative mitotic index confi  rmed that the 
bulk of the Emi1-depleted cells did not enter mitosis, whereas 
cells depleted of both Emi1 and Cdh1 accumulated in mitosis 
(Fig. 7 C). Therefore, in the absence of Cdh1, Emi1 does not 
appear to be required for cell division.
Discussion
In this study, we have shown that in contrast to the prevailing 
view, Emi1 does not regulate the APC/C at the beginning of mi-
tosis but is essential for cells to enter mitosis by inhibiting the 
APC/C to allow mitotic cyclins to accumulate. In the absence 
of Emi1, APC/C
Cdh1 remains active after mitosis, but cells are 
still able to begin the next S phase and eventually rerepli-
cate their genomes because geminin continues to be degraded. 
Figure 6.  Cyclins A and B1 and geminin levels are reduced, whereas cy-
clin E increases in rereplicating cells induced by Emi1 knockdown. (A) Asyn-
chronous HeLa cells were transfected with control (siCTR) or Emi1 (siEmi1_1) 
siRNA duplexes, and samples were collected 24, 48, or 72 h after trans-
fection. Hsp70 is shown as a loading control. The asterisk denotes residual 
cyclin B1 signal. The same extracts were run on three different gels, and a 
loading control is shown for each gel. Results are representative of three 
independent experiments. (B) Asynchronous HeLa cells were transfected 
with either control (siCTR) or Emi1 (siEmi1_1) siRNA oligonucleotides, and 
cell ploidy was analyzed by ﬂ   ow cytometry. DMSO or roscovitine was 
added or not added 24 h after transfection, and cells were analyzed 24 h 
later. Results are representative of two independent experiments. (C) Cells 
were transfected as in A to analyze geminin, CDT1, and cdc6 levels. Actin 
is shown as a loading control. The asterisk denotes residual CDT1 signal. 
Results are representative of two independent experiments.EMI1 COUPLES DNA REPLICATION AND MITOSIS • DI FIORE AND PINES 433
Therefore, Emi1 is essential to couple DNA replication and mi-
tosis in the somatic cell cycle. Although Emi1 is degraded in 
prophase, this is not required to activate APC/C
Cdc20: in contrast 
to previous reports (Reimann et al., 2001a; Hsu et al., 2002), we 
fi  nd that cyclins A and B1 and securin all begin to be degraded 
at their normal times regardless of the amount of Emi1 remain-
ing in cells. Moreover, our results also show that Emi1 does not 
have a special role in protecting cyclin A from early degradation 
by the APC/C
Cdc20. These fi  ndings have implications for how the 
cell cycle is regulated and question the general model for the 
regulation and role of the APC/C in interphase.
Emi1 degradation is not required 
to activate APC/C
Cdc20
Emi1 has been reported to be degraded just before the APC/C is 
activated in mitosis, and this constitutes an important control 
point because nondegradable Emi1 blocks cells in  prometaphase 
by preventing the APC/C
Cdc20 from being activated (Reimann 
et al., 2001a; Hsu et al., 2002). Thus, Emi1 has been proposed 
to play a role in inhibiting early mitotic APC/C
Cdc20 activity 
  before the spindle checkpoint becomes active and to prevent 
the premature degradation of cyclin A in early mitosis using a 
different mechanism from the spindle checkpoint (Reimann 
et al., 2001b; Miller et al., 2006). In contrast, we fi  nd that Emi1 
begins to be degraded before NEBD, and, regardless of when 
this occurs, the timing of cyclin A degradation is unaffected. 
Furthermore, nondegradable forms of Emi1 delay cells in mito-
sis with no endogenous cyclin A remaining, and both cyclin B1 
and securin degradation start on time. Thus, Emi1 destruction is 
not a prerequisite for APC/C
Cdc20 activation, and Emi1 does not 
inhibit the early mitotic APC/C. Our results are consistent with 
results obtained in Drosophila, in which genetic analysis has shown 
that Rca1 does not act through Cdc20/fi  zzy (Grosskortenhaus 
and Sprenger, 2002).
Emi1 is targeted for destruction through phosphorylation 
by the Plk1 kinase, which creates a phosphodegron recognized 
by the SCF
β-TrCP ubiquitin ligase (Hansen et al., 2004; Moshe 
et al., 2004), and our results are consistent with the phenotype 
of cells depleted of Plk1 by siRNA or treated with a Plk1 inhibi-
tor in which Emi1 is stabilized but cyclin A is destroyed as nor-
mal in prometaphase (Kraft et al., 2003; van Vugt et al., 2004; 
  Lénárt et al., 2007).
Our results contrast with another report that cyclin A de-
gradation is delayed in Plk1 siRNA cells (Hansen et al., 2004), 
Figure 7.  Rereplication induced by Emi1 
down-regulation depends on Cdh1 activity. 
(A) Thymidine/aphidicolin-synchronized HeLa 
cells were transfected during release from 
the thymidine block with the indicated combi-
nations of siRNA oligonucleotides directed 
against glyceraldehyde-3-phosphate dehydro-
genase (negative control), Emi1, and Cdh1. 
Protein levels were analyzed at the indicated 
times after aphidicolin release. Actin is shown 
as a loading control. The asterisk denotes re-
sidual Cdh1 signal. (B) Asynchronous HeLa 
cells were transfected with siRNA oligonucleo-
tides as indicated. 72 h after transfection, cells 
were ﬁ  xed, and DNA was stained with Hoechst 
33342. The nuclear size was measured and 
plotted as in Fig. 5 D. 200–300 nuclei were 
quantiﬁ  ed for each sample. The small bars in 
the dot plot show the minimum and maximum 
values, and the box shows the ﬁ  rst and third 
quartiles. The bar in the box is the median 
value. Outliers (closed circles) and suspected 
outliers (open circles) as determined by statisti-
cal analysis are shown. (C) Cells were syn-
chronized and transfected as in A, taxol was 
added 10 h after release from aphidicolin, 
and mitotic ﬁ  gures were scored 10 h later as a 
measure of mitotic entry. About 1,500 cells 
were analyzed for each sample. (A–C) Repre-
sentative of two experiments. Bars, 30 μm. JCB • VOLUME 177 • NUMBER 3 • 2007  434
but these data were obtained on a population of cells, which is 
less accurate than the single-cell analysis we performed in this 
study. Cyclin A and B1 levels have also been reported to be 
higher when β-TrCP is missing or depleted in β-TrCP
−/− mouse 
embryonic fi  broblasts or after siRNA treatment, which impairs 
the degradation of Emi1 (Guardavaccaro et al., 2003). However, 
this effect might be indirect.
When we injected nondegradable Emi1 closer to its en-
dogenous level, about half of the cells progressed through and 
exited from mitosis with normal timing, indicating that Emi1 
does not block APC/C
Cdc20. This is consistent with β-TrCP
−/− 
mouse embryonic fi  broblasts, where Emi1 degradation is pre-
vented, which show only a minor delay in mitotic progression 
(Guardavaccaro et al., 2003), and with cells treated with the 
Plk1 inhibitor that exit mitosis when the spindle assembly 
checkpoint is abrogated (Lénárt et al., 2007). Although cyclins 
A and B1 and securin destruction begin on time in mammalian 
cells expressing supraphysiological levels of Emi1, the cells 
do delay in metaphase. However, transfecting ectopic Emi1 
produces the protein at 10–30-fold over endogenous levels 
(Lehman et al., 2006; unpublished data), yet this only delays 
the destruction of 20% or less of cyclin B1 in the cell (Fig. 
2 E). An active spindle checkpoint may not explain the delay in 
mitosis in cells expressing high levels of nondegradable Emi1 
because Mad2 is no longer localized to the kinetochores (un-
published data).
Emi1 is required in G2 to accumulate 
mitotic cyclins and prevent rereplication
Our results show that Emi1 does not regulate the APC/C in early 
mitosis, but it is essential to inhibit the APC/C in interphase 
and, thereby, prevent rereplication. We fi  nd that depleting Emi1 
by siRNA delays cells in G2 phase, specifi  cally inhibiting mi-
totic entry, and this correlates with a failure to accumulate cy-
clins A and B1, as has been previously reported in Drosophila 
Rca1 mutants (Grosskortenhaus and Sprenger, 2002) and in 
Xenopus egg extracts depleted of Emi1 (Reimann et al., 2001a). 
Consistent with our observation that Emi1 is needed to prevent 
rereplication, in Drosophila Rca1 mutant cells, the nuclei were 
enlarged and had higher DNA levels (Grosskortenhaus and 
Sprenger, 2002), and cells from embryos expressing ectopic 
Cdh1/fi   zzy-related protein also endoreduplicate (Sigrist and 
Lehner, 1997). A requirement for Emi1 in normal proliferation 
but not in rereplicating cells is also consistent with the pheno-
type of Emi1
−/− embryos, in which the inner cell mass cells die 
but the trophoblast giant cells (which undergo rereplication) are 
relatively unaffected (Lee et al., 2006). In contrast, two previous 
studies concluded that siRNA against Emi1 blocked DNA rep-
lication in mammalian cells, but one of these could not distin-
guish where in the cell cycle cells arrested (Hsu et al., 2002), 
and the other did not measure DNA replication directly (Rape 
and Kirschner, 2004).
In many organisms, mitotic cyclin–Cdk complexes pre-
vent rereplication. In yeast, the loading and fi  ring of DNA repli-
cation origins are inhibited by high cdk1 activity (Diffl  ey, 2004). 
In fi  ssion yeast (Broek et al., 1991; Hayles et al., 1994) and 
Drosophila (Lehner, 1991; Sauer et al., 1995), mutations in 
  mitotic cyclin–Cdk cause rereplication, and some mammalian 
cells also rereplicate after cdc2 is inactivated (Itzhaki et al., 
1997). However, in other vertebrate cells, geminin has a more 
important role in inhibiting rereplication (Wohlschlegel et al., 
2000). Regardless of the reliance placed by the cell on geminin 
or mitotic cyclin–Cdk complexes, Emi1 is required to prevent 
rereplication because it stabilizes both factors. During the prep-
aration of this paper, a similar conclusion was reached by 
  Machida and Dutta using human tissue culture cells (Dutta, A., 
personal communication).
Remarkably, we found that cells without Emi1 rereplicate 
with very low levels of Cdt1. This is consistent with the reduc-
tion in levels of geminin because Cdt1 stability depends on 
geminin. Cdt1 acts to load MCM complexes at DNA origins; 
therefore, it appears that the rereplication we observe has a 
reduced requirement for Cdt1 compared with normal replica-
tion, perhaps refl  ecting a difference in the behavior of the 
MCM complexes in the absence of cyclin A. In the absence 
of Emi1, there is also a substantial increase in the amount of cy-
clin E (which is not an APC/C substrate), and this correlates 
with rereplication that could be blocked by inhibiting Cdk2 
  activity with roscovitine. These results are consistent with the 
role for cyclin E–Cdk2 in endoreplication uncovered in both 
Drosophila (Knoblich et al., 1994) and mice (Geng et al., 2003; 
Parisi et al., 2003).
How is the APC/C regulated in interphase?
After mitosis, the APC/C remains active in G1 phase in both 
yeast and somatic animal cells. In budding yeast, the G1- (Amon 
et al., 1994) or S-phase (Yeong et al., 2001) cyclin–Cdks inacti-
vate the APC/C by phosphorylating Cdh1, and this is main-
tained until anaphase (Amon et al., 1994; Zachariae et al., 1998; 
Jaspersen et al., 1999). In animal cells, the APC/C is inactivated 
against a mitotic cyclin reporter at the start of S phase (Brandeis 
and Hunt, 1996). Further studies led to the proposal that Cdh1 
is phosphorylated and inactivated by cyclin A–Cdks (Lukas 
et al., 1999; Sorensen et al., 2001), but this led to a paradox 
because cyclin A is itself a substrate of the APC/C. Indeed, we 
show here that in the absence of Emi1, cyclin A is insuffi  cient to 
inhibit Cdh1 in interphase.
Subsequently, Emi1 was proposed to inactivate the APC/C 
to allow cells to enter S phase and to accumulate cyclin A that 
would then keep Cdh1 inactive (Hsu et al., 2002). However, we 
have shown that cells enter and appear to progress through S 
phase in the absence of Emi1 with normal timing and patterns 
of origin fi  ring, except that the origins continued to fi  re after 
cells reached a 4N DNA content. Thus, either the APC/C does 
not need to be inactivated for cells to replicate their DNA, which 
has implications for the current model that the APC/C targets 
several substrates involved in DNA replication (Diffl  ey, 2004), 
or the APC/C can be inactivated in S phase by a mechanism in-
dependent of Emi1 and cyclin A such that Emi1 is only required 
to inactivate the G2-phase form of the APC/C. Clearly, Emi1 is 
important for inhibition of the APC/C in G2 phase to impose di-
rectionality on the cell cycle and couple S phase with mitosis, 
but our results indicate that it is important to reopen the ques-
tion of how the APC/C is regulated in S phase.EMI1 COUPLES DNA REPLICATION AND MITOSIS • DI FIORE AND PINES 435
Materials and methods
Cell culture and synchronization
HeLa cells were cultured in Advanced DME (Invitrogen). Cells were syn-
chronized at the G1/S transition by a thymidine/aphidicolin block. The 
day after seeding, cells were blocked with 2.5 mM thymidine (Sigma-
Aldrich) for 24 h, released for 12 h, and then blocked again with 5 μg/ml 
aphidicolin (Sigma-Aldrich) for 24 h. Cells were then released into fresh 
DME. hTert-RPE cells were cultured in 10% FBS + DME-F12 medium 
(Sigma-Aldrich). For synchronization, cells were serum starved for 24 h 
and re-fed with 25% FBS-containing medium. Cell cycle analyses were 
performed by ﬂ  ow cytometry using a cytometry system (FACSCalibur; 
Becton Dickinson).
Plasmids
Chimeric Emi1 proteins were produced by PCR from IMAGE clone ID3960052 
using Advantage polymerase (CLONTECH Laboratories, Inc.). The fragment 
was cloned into the pT7-Venus-C1 vector. Emi1 mutants were generated by 
QuikChange Site-Directed Mutagenesis (Stratagene) using the following 
oligonucleotides: C C  A  G  T  A  G  A  C  T  T  T  A  T  G  A  A  G  C  C  A  G  T  G  G  C  T  A  T  T  C  C  T  C  A   (for-
ward) and T  G  A  G  G  A  A  T  A  G  C  C  A  C  T  G  G  C  T  T  C  A  T  A  A  A  G  T  C  T  A  C  T  G  G   (reverse) 
for the D144A mutant; G  A  C  T  T  T  A  T  G  A  A  G  A  C  A  G  T  G  T  C  T  A  T  T  C  C  T  C  A  T  T  T  T  C  T  C   
(forward) and G  A  G  A  A  A  A  T  G  A  G  G  A  A  T  A  G  A  C  A  C  T  G  T  C  T  T  C  A  T  A  A  A  G  T  C   
(reverse) for the G146V mutant; and C  C  A  G  T  A  G  A  C  T  T  T  A  T  G  A  A  G  A  C  G  C  T  G-
G  C  T  A  T  T  C  C  G  C  A  T  T  T  T  C  T  C  T  A  C  A  A  A  G  T  G  G   (forward) and C  C  A  C  T  T  T  G  T  A  G  A-
G  A  A  A  A  T  G  C  G  G  A  A  T  A  G  C  C  A  G  C  G  T  C  T  T  C  A  T  A  A  A  G  T  C  T  A  C  T  G  G   (reverse) for 
the S145A/S149A mutant. IRES constructs were generating by pasting the 
Emi1 D144A and Emi1 G146V sequences into pIRES2-EGFP (CLONTECH 
Laboratories, Inc.). All clones were conﬁ  rmed by automated sequencing. 
Cyclins A2 and B1 and securin constructs have been described previously 
(den Elzen and Pines, 2001; Hagting et al., 2002).
Microinjection and time-lapse imaging and analysis
Either plasmid DNA or in vitro–transcribed mRNA was used for microinjec-
tions. mRNA was transcribed from the pT7-Venus-C1 constructs, starting from 
the T7 promoter, using the mMESSAGE mMACHINE T7 Ultra kit (Ambion).
For microinjection and time-lapse microscopy, the culture medium 
was replaced with Leibovitz’s L-15 medium (Invitrogen). Plasmids or in 
  vitro–transcribed mRNA were microinjected at a concentration of 5 ng/μl 
and 1 μg/μl, respectively, into G2-phase cells using a semiautomatic mi-
croinjector (Eppendorf) on a microscope (DMIRBE or DMIRE2; Leica). DIC 
and ﬂ  uorescence images were captured every 3 min with a MicroMax 
(Princeton Instruments) or Quantix (Photometrics) cooled CCD camera us-
ing IP Lab software (Scanalytics) or a CoolSNAP HQ cooled CCD camera 
(Photometrics) and Slidebook software (Intelligent Imaging Innovations). 
Fluorescence could be detected  30 min after injecting mRNA and  90 min 
after injecting cDNA. A modiﬁ  ed version of ImageJ software (National 
  Institutes of Health) was used to quantify the amount of ﬂ  uorescence after 
background subtraction. DIC microscopy was used to monitor mitosis, and 
the mitotic phases were determined by chromosome behavior and nuclear 
morphology. Images were converted to PICT format, exported to Photo-
Shop (Adobe), and converted from 16- to 8-bit images.
To estimate the levels of Emi1 overexpression in injected cells, Venus-
Emi1 was transfected, and levels of the tagged protein were compared 
with the endogenous by quantitative immunoblotting using the Odyssey In-
frared Imaging System (LI-COR) after normalizing for the transfection efﬁ  -
ciency. The ﬂ  uorescence was then quantiﬁ  ed and compared in transfected 
versus injected cells.
RNAi
siRNA duplexes against Emi1 corresponding to the sequence G  A  T  T  G  T  G  A  T-
C  T  C  T  T  A  T  T  A  A   (siEmi1_1, which starts at 1,337 bp and overlaps the STOP 
codon) and A  C  T  T  G  C  T  G  C  C  A  G  T  T  C  T  T  C  A   (siEmi1_2, which starts at 569 
bp) and against Cdh1 (Brummelkamp et al., 2002) were synthesized 
by Dharmacon. Nontargeting siRNA against luciferase (Dharmacon) or 
  glyceraldehyde-3-phosphate dehydrogenase siRNA (Ambion) were used 
as negative control siRNAs. Oligonucleotides were transfected at a ﬁ  nal 
concentration of 50 nM according to the manufacturer’s instructions using 
Oligofectamine (Invitrogen). Asynchronously growing cells were trans-
fected, and samples were taken 24, 48, and 72 h after transfection. 28 μM 
roscovitine (Sigma-Aldrich) was added 24 h after transfection, and DNA 
content was analyzed 24 h later. 50 μM MG132 (Calbiochem) was 
added 24 h after transfection for 6 h.
To analyze the effect of siRNAs on cell cycle progression, cells were 
transfected 5 h after release from thymidine, blocked in aphidicolin, and 
analyzed after the release from aphidicolin by ﬂ  ow cytometry and Western 
blotting. 10 μM taxol (Sigma-Aldrich) was added 10 h after release from 
aphidicolin, and cells were ﬁ  xed 10 h later to quantify the mitotic index.
In the rescue experiments, 50 nM of oligonucleotide was cotrans-
fected with pT7-Venus-Emi1 using LipofectAMINE 2000 (Invitrogen) ac-
cording to the manufacturer’s protocol. The exogenous cDNA does not 
contain the 3′ untranslated region and is therefore not depleted by the 
siEmi1_1 oligonucleotide, which is directed against a region overlap-
ping the STOP codon. In the double siRNA experiments, 50 nM siRNA 
against Emi1 was cotransfected with 50 nM of either control or Cdh1 
duplexes. 100 nM of control oligonucleotides were transfected in the con-
trol sample.
Immunoﬂ  uorescence
Cells were ﬁ  xed either in 3% PFA and 2% sucrose for 5 min or in ice-cold 
methanol/acetone (1:1) for 2 min. After permeabilization (for PFA-ﬁ  xed 
cells), cells were blocked in 3% BSA-PBS–Tween 20 and then incubated 
with antibodies. All antibodies were diluted in 3% BSA-PBS–Tween 20 
(0.2%), and washes were performed with PBS–Tween 20 (0.2%). Anti–
  cyclin A antibodies AT10.3 (Cancer Research UK) and BF683 (Cell Signal-
ing) were used at 1:5,000 or 1:200, respectively. Anti–cyclin B1 antibody 
(GNS-1; BD Biosciences) was used at 1:200. Anti–aurora B antibody (Ab-
cam) was used at 1:1,000, and CREST serum (a gift from W. Earnshaw, 
University of Edinburgh, Edinburgh, UK) was used at 1:20,000. Second-
ary antibodies conjugated to AlexaFluor568 or -647 (Invitrogen) were di-
luted at 1:400. DNA was stained with Hoechst 33342.
For analysis of the different patterns of DNA replication, BrdU was 
added to a ﬁ  nal concentration of 50 μM 30 min before ﬁ  xation. In the res-
cue experiments, BrdU was added 4 h before ﬁ  xation. Cells were then 
ﬁ  xed and stained using the BrdU Detection kit (Roche). Anti-BrdU FITC-
  conjugated antibody (B44; Becton Dickinson) was used for BrdU detection 
by ﬂ  ow cytometry.
For quantiﬁ  cation of endogenous cyclins, samples were analyzed 
with a deconvolution microscope (DeltaVision Spectris; Applied Bio  systems) 
using a 60× NA 1.4 lens to collect a series of 0.2-μm z sections. Sections 
were projected on a single plane, and the total ﬂ  orescence was measured. 
Background ﬂ  uorescence was subtracted. For BrdU and Hoechst staining, 
a single section image was collected. Nuclear size was automatically mea-
sured using a threshold function in ImageJ software.
Immunoblotting
Cells were lysed directly in SDS loading buffer. Samples were then sy-
ringed, boiled, and run on NuPAGE 4–12% Bis-Tris gels except where other-
wise indicated. Proteins were transferred to a polyvinylidene diﬂ  uoride 
membrane. Membrane saturation and all of the following incubation steps 
were performed in 5% low fat milk in PBS–Tween 20 (0.2%). Anti-Emi1 an-
tibody (Zymed Laboratories) was used at 1:100. Anti–cyclin A (BF683; 
Cell Signaling), cyclin B1 (GNS-1; BD Biosciences), and cyclin E (HE12; 
Abcam) antibodies were used at 1:1,000. Antiphospho-S133 cyclin B1 
(Jackman et al., 2003) was used at 1:500. Anti-Cdh1 antibody (a gift from 
T. Hunt and J. Gannon, Cancer Research UK, Cambridge, UK) was used 
at 1:50. Anti–geminin antibody (a gift from R. Laskey, Hutchison/Medical 
Research Council Research Centre, Cambridge, UK) was used at 1:500. 
Anti-Cdt1 and anti-cdc6 antibodies (gifts from K. Helin, Biotech Research 
and Innovation Centre, Copenhagen, Denmark) were used at 1:100 and 
1:2,000, respectively. Anti-actin (AC-40; Sigma Aldrich) and anti-Hsp70 
(H-5147; Sigma-Aldrich) antibodies were used at 1:1,000 and 1:5,000, 
respectively. HRP-conjugated secondary antibodies (DakoCytomation) 
were used at 1:5,000. The antibodies were detected using ECL-plus (GE 
Healthcare) or were analyzed with the Odyssey Infrared Imaging System 
(LI-COR) for quantitative immunoblotting. Only the output levels were ad-
justed to assemble the panels in Photoshop.
Online supplemental material
Fig. S1 shows the speciﬁ  city of the Emi1 antibody and Venus Emi1 degra-
dation in hTERT-RPE cells. Fig. S2 shows mitotic cyclin degradation in 
hTERT-RPE cells injected with Venus Emi1 and in HeLa cells after the injec-
tion of untagged Emi1. Fig. S3 shows the requirement for Emi1 for mitotic 
entry using an independent Emi1 siRNA oligonucleotide. Fig. S4 shows 
that hTERT-RPE cells have the same response as HeLa cells to depleting 
Emi1 by siRNA treatment and demonstrates the speciﬁ  city of the phenotype 
by rescue with a plasmid expressing Emi1. Fig. S5 shows the rescue of mi-
totic entry in Emi1-depleted cells by codepleting Cdh1 as assayed by ﬂ  ow 
cytometry. Online supplemental material is available at http://www.jcb
.org/cgi/content/full/jcb.200611166/DC1.JCB • VOLUME 177 • NUMBER 3 • 2007  436
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